Gene therapy for HER2-positive cancer
Part of Cancer clinical trials.
This trial tests a new gene therapy for people with HER2-positive cancer. It is for two groups: those with advanced cancer that has worsened after treatment, and those with early-stage cancer at high risk of coming back. The goal is to see if the therapy can safely help shrink tumors or prevent return.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or older.
- Your cancer must be HER2-positive (a specific protein on the cancer cells).
- For part 1: your cancer is advanced or has spread, and it got worse after previous treatment. For part 2: your cancer is early-stage but has a high risk of coming back after standard treatment.
- You need to be in fairly good health (able to do most daily activities, life expectancy of at least 3 months, and good organ function).
- You cannot have active cancer in the brain or spinal cord, serious liver problems, or a history of certain heart conditions.
- You cannot be pregnant, nursing, or have had another cancer in the last 5 years (except for certain types).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new treatment for advanced HER2-negative breast cancer. Doctors will take immune cells from lymph nodes near your tumor, grow them in a lab, and then give them back to you along with chemotherapy and immunotherapy. This approach aims to help your body fight the cancer more effectively.
This Phase 2 study tests a personalized immune-therapy vaccine made from your immune cells, given with weekly paclitaxel and HER2-targeted antibodies (trastuzumab and pertuzumab). It aims to improve treatment outcomes for people with HER2-positive breast cancer before standard local treatment (like surgery and radiation).
This trial tests a combination of radiation therapy, immunotherapy, and a drug that blocks blood vessel growth for advanced HER2-negative breast cancer that has spread. It is for patients whose cancer has worsened after at least two prior treatments.
This trial tests a personalized treatment plan for HER2-positive breast cancer that has spread. It uses a blood test to track cancer DNA and adjust therapy, including treatments that may help prevent cancer from reaching the brain. The goal is to achieve long-term remission.
This trial is testing a new medicine as the first treatment for HER2-positive breast cancer that has spread or cannot be removed. It's for women who have not had chemotherapy for advanced disease.
This early-stage study tests YH32367, a drug for people whose cancer is HER2-positive. It aims to find a safe dose and see whether it can shrink HER2-positive cancers that have spread or are hard to treat.
Hear when a new HER2 Expressing Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.